These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 29155816)

  • 1. Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.
    Guery R; Henry B; Martin-Blondel G; Rouzaud C; Cordoliani F; Harms G; Gangneux JP; Foulet F; Bourrat E; Baccard M; Morizot G; Consigny PH; Berry A; Blum J; Lortholary O; Buffet P;
    PLoS Negl Trop Dis; 2017 Nov; 11(11):e0006094. PubMed ID: 29155816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica.
    Solomon M; Pavlotsky F; Leshem E; Ephros M; Trau H; Schwartz E
    J Eur Acad Dermatol Venereol; 2011 Aug; 25(8):973-7. PubMed ID: 21129042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis.
    Kosaka A; Sakamoto N; Hikone M; Imai K; Ota M; Washino T; Maeda T; Iwabuchi S
    Intern Med; 2020; 59(9):1227-1230. PubMed ID: 32378656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.
    Solomon M; Pavlotzky F; Barzilai A; Schwartz E
    J Am Acad Dermatol; 2013 Feb; 68(2):284-9. PubMed ID: 22858005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A multifocal form of cutaneous leishmaniasis caused by Leishmania infantum in an immunocompetent child treated with a short course of liposomal amphotericin B].
    Taquin H; Chiaverini C; Marty P; Lacour JP
    Ann Dermatol Venereol; 2016 Oct; 143(10):622-624. PubMed ID: 27292718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.
    López L; Vélez I; Asela C; Cruz C; Alves F; Robledo S; Arana B
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006653. PubMed ID: 30044792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative study on liposomal amphotericin B and other therapies in the treatment of mucosal leishmaniasis: A 15-year retrospective cohort study.
    Santos CR; Tuon FF; Cieslinski J; de Souza RM; Imamura R; Amato VS
    PLoS One; 2019; 14(6):e0218786. PubMed ID: 31242231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Amphotericin B Deoxycholate, Amphotericin B Colloidal Dispersion, and Liposomal Amphotericin B as Third-Line Treatments for Cutaneous and Mucocutaneous Leishmaniasis: A Retrospective Study.
    Rodríguez Galvis MC; Pérez Franco JE; Casas Vargas MY; Ordoñez Rubiano MF
    Am J Trop Med Hyg; 2020 Feb; 102(2):274-279. PubMed ID: 31820708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate.
    Basile G; Cristofaro G; Locatello LG; Vellere I; Piccica M; Bresci S; Maggiore G; Gallo O; Novelli A; Di Muccio T; Gramiccia M; Gradoni L; Gaiera G; Bartoloni A; Zammarchi L
    Int J Infect Dis; 2020 Aug; 97():204-207. PubMed ID: 32505874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Travelers with cutaneous leishmaniasis cured without systemic therapy.
    Morizot G; Kendjo E; Mouri O; Thellier M; Pérignon A; Foulet F; Cordoliani F; Bourrat E; Laffitte E; Alcaraz I; Bodak N; Ravel C; Vray M; Grogl M; Mazier D; Caumes E; Lachaud L; Buffet PA;
    Clin Infect Dis; 2013 Aug; 57(3):370-80. PubMed ID: 23633111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous leishmaniasis in Switzerland: first experience with species-specific treatment.
    Mosimann V; Neumayr A; Hatz C; Blum JA
    Infection; 2013 Dec; 41(6):1177-82. PubMed ID: 23835701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.
    Hervás JA; Martín-Santiago A; Hervás D; Rojo E; Mena A; Rocamora V; Dueñas J
    Pediatr Infect Dis J; 2012 Jan; 31(1):97-100. PubMed ID: 21829140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical mucocutaneous involvement with Leishmania donovani.
    Pulimood SA; Rupali P; Ajjampur SS; Thomas M; Mehrotra S; Sundar S
    Natl Med J India; 2012; 25(3):148-50. PubMed ID: 22963292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: A case series from Spain.
    Pérez-Jacoiste Asín MA; Carrasco-Antón N; Fernández-Ruiz M; San Juan R; Alonso-Moralejo R; González E; Andrés A; López-Medrano F; Aguado JM
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27768239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.
    Cunha MA; Leão AC; de Cassia Soler R; Lindoso JA
    Am J Trop Med Hyg; 2015 Dec; 93(6):1214-8. PubMed ID: 26483120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and treatment response of cutaneous leishmaniasis in North-West Ethiopia.
    Fikre H; Mohammed R; Atinafu S; van Griensven J; Diro E
    Trop Med Int Health; 2017 Oct; 22(10):1293-1301. PubMed ID: 28712122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cutaneous leishmaniasis treated with ambisome (liposomal amphotericin B)].
    Ben-Shimol S; Sagi O; Schwartz E; Greenberg D
    Harefuah; 2012 Aug; 151(8):458-60, 498. PubMed ID: 23350289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
    Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapidly progressing facial leishmaniasis: effective treatment with liposomal amphotericin B and a review of the management of Old World cutaneous leishmaniasis.
    Islam S
    Paediatr Int Child Health; 2018 May; 38(2):158-161. PubMed ID: 28281913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital.
    Garrido-Jareño M; Sahuquillo-Torralba A; Chouman-Arcas R; Castro-Hernández I; Molina-Moreno JM; Llavador-Ros M; Gómez-Ruiz MD; López-Hontangas JL; Botella-Estrada R; Salavert-Lleti M; Pemán-García J
    Parasit Vectors; 2020 Jan; 13(1):24. PubMed ID: 31931865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.